SAREPTA THERAPEUTICS INC (SRPT) Stock News

Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years

Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement and minimal muscle pathology progression.

Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS

What 14 Analyst Ratings Have To Say About Sarepta Therapeutics

Biogen, Sarepta Quick Drug Approvals Show FDA Gaps, Report Says

Approvals for drugs from Biogen Inc. and Sarepta Therapeutics Inc. show flaws in the process US drug regulators use to speed approval for drugs to fill unmet needs, federal watchdogs said in a report.

Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

/PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced that management will attend the 43rd Annual J.P. Morgan...

Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arrowhead Launches 25% On A Massive Licensing Deal With Sarepta

The deal focuses on four clinical-stage drugs, three preclinical assets and a potential five new targets.

Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs

Sarepta Therapeutics (SRPT) Q3 2024 Earnings Call Transcript

SRPT earnings call for the period ending September 30, 2024.

Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up

The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.

2 High-Flying Growth Stocks With Massive Upside Potential

These innovative drugmakers have potential catalysts ahead.